GTC Biotherapeutics Company Profile

20:34 EDT 17th March 2018 | BioPortfolio

GTC Biotherapeutics develops, produces, and commercializes therapeutic proteins using transgenic animal technology. ATryn®, recombinant human antithrombin, is the first transgenically produced therapeutic protein approved anywhere in the world, having recently been approved by the European Commission (EMEA) for the prophylactic treatment of deep vein thrombosis in patients with hereditary antithrombin deficiency. ATryn® was approved for hereditary antithrombin deficiency in the United States (FDA) in February 2009, and remains the only recombinant form of the molecule available for clinical use. ATryn® is produced in the milk of goats using micro-injection technology to incorporate a human antithrombin transgene. In addition to ATryn®, GTC is developing additional recombinant proteins and monoclonal antibodies. These products have potential applications in hematology, oncology, and autoimmune diseases. GTC has active development and commercialization relationships with Lundbeck Inc. and LFB Paris.


175 Crossing Blvd.
United States of America


Phone: (508) 620-9700
Fax: (508) 370-3797

News Articles [174 Associated News Articles listed on BioPortfolio]

#jobs #lifescience MS Applications Chemist – Biotherapeutics

Biotechnology, Pharma and Biopharma News – Research – Science – Lifescience ://Biotech-Biopharma-Pharma: MS Applications Chemist – Biotherapeutics .MA-Boston, MS Applications Chemi...

BRIEF—Hangzhou Just Biotherapeutics opens R&D center and GMP manufacturing facility

China-based Hangzhou Just Biotherapeutics (HJB), an organization dedicated to expanding global access…

ATUM, Just Biotherapeutics collaborate to speed up drug discovery

ATUM has signed a patent licensing agreement, which gives Just Biotherapeutics access to its Leap-In cell line development tools.

ATUM, Just Biotherapeutics collaborate to accelerate drug discovery

ATUM has entered into a patent licensing agreement with Just Biotherapeutics, providing access to the company’s Leap-In cell line development tools.

Protalix BioTherapeutics Treatment for Ulcerative Colitis Shows Positive Data

Protalix BioTherapeutics believes it’s on the right track in developing an oral medicine for ulcerative colitis that could potentially replace current TNF-inhibitor therapies that are administered v...

3 Best Biotherapeutics Stocks to Buy Right Now

Sometimes the biggest are also the best. That's the case for biotherapeutics stocks.

Stealth BioTherapeutics Granted Fast Track Designation for Elamipretide for the Treatment of Leber’s Hereditary Optic Neuropathy

BOSTON – December 18, 2017 – Stealth BioTherapeutics (Stealth), a clinical-stage biopharmaceutical company developing therapeutics to treat mitochondrial dysfunction, today announced that the U.S....

Aeglea BioTherapeutics Updates Phase I/II Trial Data

Aeglea BioTherapeutics announced new repeat dose data from its Phase I/II trial of AEB1102 (pegzilarginase) in patients with Arginase 1 Deficiency.

Drugs and Medications [14 Associated Drugs and Medications listed on BioPortfolio]


Plasma Protein Fraction (Human) 5%, USPPlasmanate®


Immune Globulin (Human)GamaSTAN™ S/DSolvent/Detergent Treated


Albumin (Human) 5%, USPPlasbumin ®-5


Albumin (Human) 5%, USPPlasbumin ®-5


Albumin (Human) 20%, USPPlasbumin®-20

PubMed Articles [22 Associated PubMed Articles listed on BioPortfolio]

Toward best practices in data processing and analysis for intact biotherapeutics by MS in quantitative bioanalysis.

Typically, quantitation of biotherapeutics from biological matrices by LC-MS is based on a surrogate peptide approach to determine molecule concentration. Recent efforts have focused on quantitation o...

Glycosimilarity assessment of biotherapeutics 1: Quantitative comparison of the N-glycosylation of the innovator and a biosimilar version of etanercept.

The carbohydrate moieties on the polypeptide chains in most glycoprotein based biotherapeutics and their biosimilars play essential roles in such major mechanisms of actions as antibody-dependent cell...

Targeting Receptor-Type Protein Tyrosine Phosphatases with Biotherapeutics: Is Outside-in Better than Inside-Out?

Protein tyrosine phosphatases (PTPs), of the receptor and non-receptor classes, are key signaling molecules that play critical roles in cellular regulation underlying diverse physiological events. Abe...

Population-specific design of de-immunized protein biotherapeutics.

Immunogenicity is a major problem during the development of biotherapeutics since it can lead to rapid clearance of the drug and adverse reactions. The challenge for biotherapeutic design is therefore...

Meeting report WHO informal consultation on development of guidelines on procedures and data requirements for changes to approved biotherapeutic products, Seoul, Republic of Korea, 27-28 April 2017.

In April 2017, WHO convened an informal consultation to develop WHO guidelines on procedures and data requirements for changes to approved biotherapeutic products. The objective of the meeting was to ...

Clinical Trials [4 Associated Clinical Trials listed on BioPortfolio]

Safety and Pharmacokinetics Study of Anthrax Immune Globulin Intravenous (AIGIV)

The purpose of this study is to: - evaluate the safety profile of a single intravenous administration of AIGIV (containing either 3.5 mg/kg, 7.0 mg/kg or 14.0 mg/kg anti-PA IgG) a...

A Study to Evaluate the Safety, Tolerability, and Efficacy of Subcutaneous Injections of Elamipretide (MTP-131) in Subjects With Genetically Confirmed Mitochondrial Disease Previously Treated in the Stealth BioTherapeutics SPIMM-201 Study

This is a Phase 2, randomized, double-blind, placebo-controlled crossover study which will enroll up to 36 subjects (anticipated) with genetically confirmed mitochondrial disease who have ...

The Effect of OASIS Ultra on Critical Sized Wound Healing

The aim of this study is to evaluate the speed and quality with which OASIS® Ultra (Healthpoint Biotherapeutics; Fort Worth, Texas) increases wound healing in the critical sized defect. ...

Personalized Immunotherapeutics for Antibiotic-resistant Infection

M. A. suffers from hypogammaglobulinemia that has been complicated by refractory Mycoplasma hominis septic arthritis. He has been receiving the antibiotic valnemulin under Emergency Invest...

Companies [95 Associated Companies listed on BioPortfolio]

Axial Biotherapeutics

Axial Biotherapeutics is a biopharmaceutical company harnessing the link between the human gut microbiome and the central nervous system to develop a new class of biotherapeutics ...

Napro Biotherapeutics Incorporated

NaPro BioTherapeutics, Inc. is a natural product pharmaceutical company focused primarily on the development, manufacture and commercializa tion of paclitaxel, a naturally-occurring anti-cancer agent ...

Sephos Biotherapeutics

Sephos Biotherapeutics is a privately owned company focused on designing drugs for the treatment of cancer stem cells where the structure and biological activity of the drugs have...

Talecris Biotherapeutics Holdings Inc.

Talecris Biotherapeutics (Nasdaq: TLCR) is a global biotherapeutic and biotechnology company that discovers, develops and produces critical care treatments for people with life-threatening disorders i...

Talecris Biotherapeutics, Inc.

Talecris Biotherapeutics (Nasdaq: TLCR) is a global biotherapeutic and biotechnology company that discovers, develops and produces critical care treatments for people with life-th...

More Information about "GTC Biotherapeutics" on BioPortfolio

We have published hundreds of GTC Biotherapeutics news stories on BioPortfolio along with dozens of GTC Biotherapeutics Clinical Trials and PubMed Articles about GTC Biotherapeutics for you to read. In addition to the medical data, news and clinical trials, BioPortfolio also has a large collection of GTC Biotherapeutics Companies in our database. You can also find out about relevant GTC Biotherapeutics Drugs and Medications on this site too.

Quick Search


Relevant Topic

Gene Therapy
Gene therapy is the use of DNA as a pharmaceutical agent to treat disease. It derives its name from the idea that DNA can be used to supplement or alter genes within an individual's cells as a therapy to treat disease. The most common form of gene th...

Corporate Database Quicklinks

Searches Linking to this Company Record